Kesin Pharma Logo (Kesin Logo)
Topiramate Solution
Product Images NDC 81033-035
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 81033-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Kesin Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Topi-25-b (Topi 25 B)
Topiramate Oral Solution 25 mg/mL in a 473 mL container. The label states it is for oral use only and prescription use (Rx Only). Instructions highlight dispensing the product with an oral dosing syringe and medication guide. Manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Bedminster, NJ. The label includes storage instructions, a barcode, and space for batch details and expiration date.*
Topi-25mg-120ml-cart (Topi 25mg 120ml Cart)
Packaging label for Topiramate Oral Solution 25 mg/mL, 120 mL, distributed by Ascend Laboratories, LLC. The label states it is for oral use only, prescription only (Rx Only), and includes instructions for pharmacists to dispense an oral dosing syringe and medication guide with each patient. The label also includes storage instructions, a website link for the medication guide, and manufacturer information for Alkem Laboratories Ltd., Mumbai, India.*
Topi-fig-1 (Topi Fig 1)
A line chart showing cumulative rates for time to first seizure over a period of 500 days comparing Topiramate 50 mg/day and 400 mg/day dosages. The x-axis represents time in days and the y-axis represents cumulative rates, with the higher dose showing lower cumulative rates of seizure.*
Topi-fig-2 (Topi Fig 2)
A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rates for placebo and Topiramate dosed at 50 mg/day, 100 mg/day, and 200 mg/day across two studies (Study 11 and Study 12). The chart shows decreasing migraine rates with increasing Topiramate dose and indicates statistical significance levels (* p<0.010, ** p<0.001) for the higher doses in both studies.*
Topi-stru (Topi Stru)
Chemical structure of Topiramate, showing its specific molecular framework including ring systems, oxygen, sulfur, and nitrogen atoms as part of its chemical composition.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
